Evidence map›Paper›PMID 28079591›Full record

ReviewCurrent opinion in HIV and AIDS2017

Point-of-care diagnostics: extending the laboratory network to reach the last mile.

Paul K Drain, Christine Rousseau

Erratum issuedAbstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Using HIV antibody measurements to detect viral load rebound: An analysis from an analytic treatment interruption study in the United States.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Observational
  3. Review
  4. A Generalizable Decision-Making Framework for Selecting Onsite versus Send-out Clinical Laboratory Testing.Medical decision making : an international journal of the Society for Medical Decision Making · 2024
    Article
  5. Nucleic Acid Point-of-Care Testing to Improve Diagnostic Preparedness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Performance evaluation of the MedMira reveal G4 LAB S/P and POC HIV antibody rapid screening tests using plasma and whole blood specimens.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020
    Article
  11. Observational
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Paul K DrainaDepartment of Global Health bDepartment of Medicine cDepartment of Epidemiology, University of Washington, Seattle, Washington dDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts eBill and Melinda Gates Foundation, Seattle, Washington, USA.
Christine Rousseau

Funding

Clinic-based Screening to Prevent HIV-associated Cryptococcal MortalityK23AI108293 · NIAID · UNIVERSITY OF WASHINGTON · PI DRAIN, PAUL K · 2014 to 2018
$928k
A Point-of-Care Assay to Measure Tenofovir for Monitoring PrEP and ART AdherenceR21AI127200 · NIAID · UNIVERSITY OF WASHINGTON · PI DRAIN, PAUL K · 2016 to 2017
$396k
Point-of-care viral load testing to enable task shifting for chronic HIV careR21AI124719 · NIAID · UNIVERSITY OF WASHINGTON · PI DRAIN, PAUL K, GARRETT, NIGEL JOEL · 2016 to 2017
$336k
NIAID NIH HHS K23 AI108293NIAID NIH HHS R21 AI124719NIAID NIH HHS R21 AI127200
6 · The paper itself

Abstract

purpose of reviewMore point-of-care (POC) diagnostic tests are becoming available for HIV diagnosis and treatment in resource-limited settings. These novel technologies have the potential to foster decentralized HIV care and treatment for the benefit of clinical laboratories, HIV clinics, and HIV-infected patients. There continue to be many business, technological, and operational challenges that limit product development and regulatory approval, which limits products available for the required operational and cost-effectiveness studies and delays policy adoption and implementation. RECENT

findingsAlthough the rapid HIV diagnostic test has been widely successful, the pathways for POC CD4 cell count and HIV viral load assay analyzers have been more challenging. We describe significant hurdles for product development, approval, and implementation, which include the business case, technical development, clinical impact, and integrating laboratory and clinical networks. SUMMARY: The objective of this review is to highlight the obstacles for developing and implementing appropriate strategies for POC HIV testing assays to improve the clinical services for HIV-infected patients in resource-limited settings.

Indexed as

Point-of-Care SystemsCD4 Lymphocyte CountHIV InfectionsHumansViral Load

Identifiers

PMID28079591
PMCPMC5287256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.